Amazon.com, Inc. (AMZN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Amazon.com, Inc. (AMZN)

AMZN 234.70

-1.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mark Fowler who wrote (116186)	1/25/2001 4:22:04 PM
From: H James Morris	Read Replies (1) of 164684

Mark, prudential can shove it. I'm in Imnx until the end! Immunex has a problem...more demand than supply. That can fixed. Trust me. >NEW YORK, Jan 25 (Reuters) - Prudential Securities said it cut its price target on shares of drug maker Immunex Corp. a day after the company said manufacturing limits remained for its rheumatoid arthritis treatment Enbrel. Prudential analyst Robert Toth cut his 12-month target on Immunex stock to $40 per share from $55 per share. Shares slumped $1-7/16, or more than 4 percent, to $32-15/16 in afternoon trade. Toth said in a research note that the capacity issue has caused him to lower 2001 estimates for Enbrel to $750 million from $850 million. Enbrel sales in 2000 were $652 million, the company said in its fourth-quarter earnings release. "While we anticipate numerous advancements on all product fronts for Immunex in 2001, we believe that the overshadowing presence of Enbrel supply constraints could dampen investor enthusiasm," Toth said. REUTERS Rtr 15:43 01-25-01

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next